CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      Background: Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer (LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used serum marker in breast cancer. Methods: We retrospectively investigated the role of CA 15-3 in conjunction with other clinicopathological variables as a predictor of response and time to disease recurrence following treatment in LABC. Pre and post primary chemotherapy serum concentrations of CA 15-3 together with other variables were reviewed and related to four outcomes following primary chemotherapy (clinical response, pathological response, time to recurrence and time to progression). Persistently elevated CA 15-3 after PC was considered as consecutively high levels above the cut off point during and after PC. Results: 73 patients were included in this study. Patients received PC (AC or AC-T regimen) for locally advanced breast cancer. 54 patients underwent surgery. The median follow up was 790 days. Patients with high concentrations of CA 15-3 before PC treatment had a poor clinical (p = 0.013) and pathological (p = 0.044) response. Together with Her-2/neu expression (p = 0.009) and tumour lympho-vascular space invasion (LVI) (p = 0.001), a persistently elevated CA 15-3 post PC (p =0.007) was an independent predictive factor of recurrence following treatment in LABC. Conclusion: Elevated CA 15-3 level is predictive of a poor response to chemotherapy. In addition, persistently elevated CA 15-3 levels post chemotherapy in conjunction with lympho-vascular invasion and HER2 status predict a reduced disease free survival following treatment in locally advanced breast cancer. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of BMC Cancer is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • Author Affiliations:
      1Department of Surgery, St. Vincent's University Hospital, Dublin, Ireland,
      2Royal College of Surgeons in Ireland, 123 St. Stephens Green, Dublin, Ireland
      3School of Mathematical Sciences, University College Dublin,Dublin, Ireland,
      4Department of Nuclear Medicine, St.Vincent's University Hospital, Dublin, Ireland
    • ISSN:
      1471-2407
    • Accession Number:
      10.1186/1471-2407-6-220
    • Accession Number:
      29336864
  • Citations
    • ABNT:
      AL-AZAWI, D. et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer, [s. l.], v. 6, p. 220–7, 2006. DOI 10.1186/1471-2407-6-220. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=a9h&AN=29336864&custid=s6224580. Acesso em: 5 abr. 2020.
    • AMA:
      Al-azawi D, Kelly G, Myers E, et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer. 2006;6:220-227. doi:10.1186/1471-2407-6-220.
    • APA:
      Al-azawi, D., Kelly, G., Myers, E., McDermott, E. W., Hill, A. D., Duffy, M. J., & Higgins, N. O. (2006). CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer, 6, 220–227. https://doi.org/10.1186/1471-2407-6-220
    • Chicago/Turabian: Author-Date:
      Al-azawi, Dhafir, Gabrielle Kelly, Eddie Myers, Enda W McDermott, Arnold DK Hill, Michael J Duffy, and Niall O Higgins. 2006. “CA 15-3 Is Predictive of Response and Disease Recurrence Following Treatment in Locally Advanced Breast Cancer.” BMC Cancer 6 (January): 220–27. doi:10.1186/1471-2407-6-220.
    • Harvard:
      Al-azawi, D. et al. (2006) ‘CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer’, BMC Cancer, 6, pp. 220–7. doi: 10.1186/1471-2407-6-220.
    • Harvard: Australian:
      Al-azawi, D, Kelly, G, Myers, E, McDermott, EW, Hill, AD, Duffy, MJ & Higgins, NO 2006, ‘CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer’, BMC Cancer, vol. 6, pp. 220–7, viewed 5 April 2020, .
    • MLA:
      Al-azawi, Dhafir, et al. “CA 15-3 Is Predictive of Response and Disease Recurrence Following Treatment in Locally Advanced Breast Cancer.” BMC Cancer, vol. 6, Jan. 2006, pp. 220–7. EBSCOhost, doi:10.1186/1471-2407-6-220.
    • Chicago/Turabian: Humanities:
      Al-azawi, Dhafir, Gabrielle Kelly, Eddie Myers, Enda W McDermott, Arnold DK Hill, Michael J Duffy, and Niall O Higgins. “CA 15-3 Is Predictive of Response and Disease Recurrence Following Treatment in Locally Advanced Breast Cancer.” BMC Cancer 6 (January 2006): 220–27. doi:10.1186/1471-2407-6-220.
    • Vancouver/ICMJE:
      Al-azawi D, Kelly G, Myers E, McDermott EW, Hill AD, Duffy MJ, et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer [Internet]. 2006 Jan [cited 2020 Apr 5];6:220–7. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=a9h&AN=29336864&custid=s6224580